Loading...

140 posters, 10 videos, 15 audios, 20 sessions, 508 authors, 204 institutions

ePostersLive by SciGen Technologies S.A. All rights reserved.

8th World Congress on Vascular Access 2024

April 17 - 19, 2024 | Prague, Czech Republic

8th World Congress on Vascular Access 2024 banner

175

Risk factors and biomarker profiles associated with pediatric arterial catheter- associated proximal ischemic injuries. 

Part of Topic

Risk Factors and Biomarker Profiles Associated with Pediatric Arterial Catheter- Associated Proximal Ischemic Injuries

 

Background

•Critically ill patients frequently require arterial access for hemodynamic management and blood sampling
•
•Some patients who require arterial access may exhibit dysregulation of their microvascular circulation 
•
•Dysregulation combined with the presence of an arterial catheter can put the surrounding tissues at risk for injury
•
•Arterial Catheter Associated Proximal Ischemic Injury (ACAPII) can present with various degrees of injury
•
•Previous institutional work has defined mild ACAPII as exhibiting blanching, erythema and ecchymosis 
•
•Severe ACAPII includes the progression to an open wound or severe diminished distal pulses
 
Objective 
 
•Identify risk factors, including biomarker profiles, associated with AC-associated ischemic injuries in critically children
 
Methods
•Retrospective analysis of arterial catheters placed in children > 1 month and < 18 years from January 2020 to December 2022 in a single center pediatric intensive care unit
•
•Assessment of patient, provider and device related factors
•
•Additional assessment using a biomarker repository data comparing a subset of patients with ACAPII with control patients 
 
Results 

2111 index arterial catheters were evaluated (45% female)

Incidence of ACAPII

  72 patients had an episode of ACAPII, 12 of which has severe ACAPII

 

Patient Related Factors Seen in ACAPII    ------------>    sicker and smaller patients

  Younger age (5.2 (0.9, 12.2) vs 8.5 (2.8, 14.6)

  Higher vasopressor usage (62% vs. 40%; p<0.01)

  Higher PIM3 ROM (3 [1,5] vs. 1 [0,3]; p<0.01).

 

Provider Related Factors

  No significance related to vessel accessed or insertion attempts

 

Device Related Factors Seen in ACAPII    ------------->    more frequent in smaller patient

  Smaller catheters 24g  (39% vs. 11%; p<0.01) 

  Shorter Catheters < 2.5 cm (31% vs. 12%)

 

Biomarker Data Seen in ACAPII                  ------------>      mimics thrombotic microangiopathies

  Lower platelets (168 [57,230] vs. 199 [133,267]; p=0.01), 

  Elevated D- Dimer dimer (20 [6,31] vs. 4 [1,12]; p=0.03), 

  Decreased Albumin  (2.5 [2.3,3.18] vs. 2.8 [2.3,3.5] p=0.04) 

  Lower pH (pH 7.23 (7.15,7.33) vs. 7.31 (7.24,7.38); p<0.01)

 

Plasma Protein Expression Seen in ACAPII   --------->     genetic predilection to microthrombi during illness

   (biobank data of 5 patients with ACAPII compared to 66 without)

   Increased expression of TSLP, LIF, and IL24,  proinflammatory factors related to endothelial dysfunction

   These three factors  lead to signaling of the Stat3 pathway

   Stat3 signaling leads to a protein scaffold encouraging platelet activation

   The platelet activation can lead to increased microthrombi in certain critically ill children

 

Conclusions

•We identified candidate pathways of immune dysregulation and endothelial dysfunction at MODS onset which are associated with the development of arterial catheter associated proximal ischemic injury. 
•
•These injuries likely develop in the setting of hyperinflammation, endothelial dysfunction, and platelet aggregation.
•
•Further studies linking these dysregulated pathways to platelet aggregation and thrombosis could suggest new therapeutic targets for pediatric patients at risk for ACAPII
•
•Increased use of Papaverine may limit occurrence of severe ACAPII
•
•Further validation of the grading scales with inter-rater reliability would improve diagnostic accuracy
8th World Congress on Vascular Access 2024 » banner
Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.